265 related articles for article (PubMed ID: 17545756)
21. A novel c.1255G>T (p.D419Y) mutation in SH3BP2 gene causes cherubism in a Turkish family.
Dinckan N; Guven Y; Kayserili H; Aktoren O; Uyguner OZ
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Nov; 114(5):e42-6. PubMed ID: 23083484
[TBL] [Abstract][Full Text] [Related]
22. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
23. [Cherubism].
Brix M; Peters H; Lebeau J
Rev Stomatol Chir Maxillofac; 2009 Nov; 110(5):293-8. PubMed ID: 19836038
[TBL] [Abstract][Full Text] [Related]
24. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism.
Lo B; Faiyaz-Ul-Haque M; Kennedy S; Aviv R; Tsui LC; Teebi AS
Am J Med Genet A; 2003 Aug; 121A(1):37-40. PubMed ID: 12900899
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic and Molecular Characteristics of Familial Cherubism with Associated Odontogenic Tumorous Proliferations.
Argyris PP; Gopalakrishnan R; Hu Y; Reichenberger EJ; Koutlas IG
Head Neck Pathol; 2018 Mar; 12(1):136-144. PubMed ID: 28721660
[TBL] [Abstract][Full Text] [Related]
26. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
[TBL] [Abstract][Full Text] [Related]
27. A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism.
Imai Y; Kanno K; Moriya T; Kayano S; Seino H; Matsubara Y; Yamada A
Cleft Palate Craniofac J; 2003 Nov; 40(6):632-8. PubMed ID: 14577811
[TBL] [Abstract][Full Text] [Related]
28. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics.
Guimarães LM; Baumhoer D; Andrei V; Friedel D; Koelsche C; Gomez RS; von Deimling A; Gomes CC
J Pathol Clin Res; 2023 Nov; 9(6):464-474. PubMed ID: 37555357
[TBL] [Abstract][Full Text] [Related]
30. Expression of bone morphogenetic proteins in giant cell tumor of bone.
Kudo N; Ogose A; Ariizumi T; Kawashima H; Hotta T; Hatano H; Morita T; Nagata M; Siki Y; Kawai A; Hotta Y; Hoshino M; Endo N
Anticancer Res; 2009 Jun; 29(6):2219-25. PubMed ID: 19528484
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
32. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.
Yoshitaka T; Kittaka M; Ishida S; Mizuno N; Mukai T; Ueki Y
Bone; 2015 Feb; 71():201-9. PubMed ID: 25445458
[TBL] [Abstract][Full Text] [Related]
34. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
[TBL] [Abstract][Full Text] [Related]
36. Analysis of giant cell tumour of bone cells for Noonan syndrome/cherubism-related mutations.
Moskovszky L; Idowu B; Taylor R; Mertens F; Athanasou N; Flanagan A
J Oral Pathol Med; 2013 Jan; 42(1):95-8. PubMed ID: 22725657
[TBL] [Abstract][Full Text] [Related]
37. Clinical and genetic analysis of patients with cherubism.
Machado RA; Pontes H; Pires FR; Silveira HM; Bufalino A; Carlos R; Tuji FM; Alves D; Santos-Silva AR; Lopes MA; Capistrano HM; Coletta RD; Fonseca FP
Oral Dis; 2017 Nov; 23(8):1109-1115. PubMed ID: 28644570
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a Norwegian cherubism cohort; molecular genetic findings, oral manifestations and quality of life.
Prescott T; Redfors M; Rustad CF; Eiklid KL; Geirdal AØ; Storhaug K; Jensen JL
Eur J Med Genet; 2013 Mar; 56(3):131-7. PubMed ID: 23298620
[TBL] [Abstract][Full Text] [Related]
39. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
40. Cherubism - new hypotheses on pathogenesis and therapeutic consequences.
Hyckel P; Berndt A; Schleier P; Clement JH; Beensen V; Peters H; Kosmehl H
J Craniomaxillofac Surg; 2005 Feb; 33(1):61-8. PubMed ID: 15694152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
